Applied Imaging Corp. (AICX) - 500 Beiträge pro Seite
eröffnet am 03.11.05 16:50:39 von
neuester Beitrag 02.02.06 09:23:47 von
neuester Beitrag 02.02.06 09:23:47 von
Beiträge: 14
ID: 1.017.489
ID: 1.017.489
Aufrufe heute: 0
Gesamt: 730
Gesamt: 730
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 44 Minuten | 6289 | |
| vor 35 Minuten | 3842 | |
| vor 57 Minuten | 2314 | |
| vor 1 Stunde | 2252 | |
| heute 09:10 | 1908 | |
| vor 37 Minuten | 1793 | |
| vor 1 Stunde | 1623 | |
| heute 11:56 | 1330 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.000,48 | -0,49 | 223 | |||
| 2. | 3. | 151,90 | +0,22 | 99 | |||
| 3. | 2. | 9,5050 | -1,45 | 91 | |||
| 4. | 4. | 0,1875 | -3,35 | 80 | |||
| 5. | 6. | 0,0211 | -32,59 | 53 | |||
| 6. | 34. | 0,6200 | -55,71 | 47 | |||
| 7. | 13. | 389,30 | -15,65 | 45 | |||
| 8. | 5. | 6,8400 | +1,42 | 42 |
Feedback
Profile:Applied Imaging Corp. engages in the development, manufacture, and marketing of automated genetic imaging systems for use in cytogenetic laboratories worldwide. Its systems analyze human chromosome preparations using software classification algorithms and an user interface. These systems also incorporate the capability to analyze and record images produced by advanced genetic research assays. The company’s systems are used for cancer testing, prenatal testing, and other genetic testing applications. Applied Imaging also markets imaging systems designed for use in plant and animal genetic research programs. In addition, it offers a clinical system that assists in the detection of micrometastatic cancer cells in bone marrow. The company sells its products to government and private clinical laboratories, research institutions, universities, and pharmaceutical companies through a direct sales force, third-party distributors, and independent sales representatives. Applied Imaging was founded in 1986 and is headquartered in San Jose, California.
http://www.aicorp.com/
http://www.aicorp.com/
ganz klarer kauf
notiert am cash
notiert am cash
Applied Imaging Announces Third Quarter 2005, Nine Month Results
* Q3 Revenue $4.9 Million, Year-to-Date $14.7 million * Increased Investment in Circulating Tumor Cell Application Development
SAN JOSE, Calif., Nov 14, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Applied Imaging Corp. ("Applied Imaging") (Nasdaq: AICX), the leading supplier of automated digital imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications, today announced financial and operating results for the third quarter and nine month period ended September 30, 2005.
Total revenues for the quarter ended September 30, 2005 were $4.9 million. Revenues for the comparable period in 2004, at $5.7 million, were positively impacted by the release of Ariol 2.0, allowing system sale deferrals of $0.8 million from prior periods to be recognized.
Total revenues for the nine months ended September 30, 2005 were $14.7 million. This compares to revenues for the first nine months of 2004 of $14.9 million. Revenues for the first nine months of 2004 included system sale deferrals related to the release of Ariol 2.0 of $0.8 million.
The Company`s operating loss for the three months ended September 30, 2005 was $71,000 versus an operating loss of $242,000 for the equivalent period in 2004. The operating loss for the nine months ended September 30, 2005 was $850,000 compared to an operating loss for the first nine months of 2004 of $1.8 million.
The Company`s net loss for the three months ended September 30, 2005 was $362,000 versus a net loss of $237,000 for the equivalent period in 2004. The net loss for the nine months ended September 30, 2005 was $1.3 million compared to a net loss for the first nine months of 2004 of $1.9 million.
Robin Stracey, President and CEO, said, "We are pleased with our progress this quarter. Third quarter revenues were again in line with our expectation and though our net income was negatively impacted by adverse fluctuations in the dollar-pound exchange rate and the settlement of our tax dispute with the Inland Revenue in the UK, we came close to operating profitability this quarter in spite of our increased level of investment in the circulating tumor cell initiative. We had previously disclosed the tax dispute as a contingent liability of $1.1 million and were pleased to be able to finally settle the matter for $211,000."
Gross profit for the quarter was $3.2 million, representing a gross margin of 65%, up from 56% for the third quarter of 2004. Gross margin for the nine months ending September 2005 was 61%, up from 59% in the comparable prior year period.
Operating expenses for the quarter, inclusive of $515,000 for the CTC, Inc. subsidiary, were $3.3 million, a 5% decrease from the $3.4 million in the third quarter of 2004. Operating expenses for the nine-month period ended September 30, 2005, inclusive of $1.1 million for the CTC, Inc. subsidiary, were $9.8 million, an 8% decrease from the $10.6 million for the comparable 2004 period.
"2005 to date has been devoted to resolving legacy issues, solidifying the performance of our core imaging business and pushing forward with our circulating tumor cell initiative", continued Mr. Stracey. "There are three key elements to our long term growth strategy. Firstly, we intend to continue to enhance the profitability of our clinical cytogenetics business through the incremental rollout of high value new software releases, leverage of our installed base of over 4,000 units around the world and ongoing productivity improvement initiatives. Secondly, we intend to capitalize on the unique attributes of our Ariol(R) pathology workstation as a powerful tool for biopharma companies evaluating the efficacy of candidate cancer drugs. Seven leading biopharma companies have now purchased at least one Ariol(R) and we expect to further enhance the system`s value and our opportunity going forward by expanding our offering to include additional, fee-based, customization services. Thirdly, we intend to continue to invest directly, and with a strategic partner, in the development of a leading edge system for the detection, quantification and analysis of tumor cells in the circulating blood of cancer patients. We anticipate that this system, designed around the established analytical capabilities of the Ariol(R) platform, would have the potential to transform the diagnosis and monitoring of the disease and would introduce the Company to what is expected to be a significant new growth market. Additionally, we continue to focus on efficiency and process improvement."
Mr. Stracey added, "Against these goals, we accomplished a number of key milestones in the third quarter. In cytogenetics, we released CytoVision 3.7, the third in a series of important new releases this year aimed at strengthening our competitive position and further enhancing the profitability of our clinical cytogenetics business. In pathology, we released Ariol(R) 2.1 and added several important new accounts to our marquee list of biopharma and translational research customers. In CTC we made progress in our efforts to adapt the Ariol(R) rare cell detection algorithm for use with circulating tumor cells and in our efforts to optimize several of the components of the kit that we anticipate will be the captive consumable component of the system. And a good example of our progress in process improvement is the 58% reduction we have seen in inventory between December 2004 and September 2005 as a result of the adoption of more efficient supply chain management practices."
Financial Condition
As of September 30, 2005, the Company had cash and cash equivalents of $3.2 million, compared to $3.0 million at June 30, 2005 and $3.9 million at December 31, 2004.
Outlook
The Company reaffirms its full year revenue projection of approximately $20 million and expects to achieve operating profitability in its core imaging business in the fourth quarter.
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications. The Company develops, manufactures and markets a range of scanning and image analysis systems for both conventional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens. Products are sold to hospital laboratories, cancer centers, prenatal clinics and research institutions for both research and clinical purposes. The Company has installed over 4,000 of its systems in over 1000 laboratories in more than 60 countries around the world. Beyond its core business, through its wholly-owned subsidiary, CTC, Inc., the Company is also developing a system for the detection, quantification and characterization of tumor cells in the blood of cancer patients.
More information about Applied Imaging can be found at www.aicorp.com.
Code: AICXG
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements as defined in the Private Securities Litigation Reform Act of 1995, regarding, among other matters, the timing of the Company`s Cytovision and Ariol software releases, its ability to execute its long term growth initiatives, including successful development of its circulating tumor cell system and adapting its Ariol platform to new applications, as well as its future financial performance, financial condition, timing of operating profitability in its core imaging business, and the timing and amount of spending for its CTC, Inc. subsidiary. Forward-looking statements are based on management`s current, preliminary, expectations and are subject to risks and uncertainties, which may cause the Company`s actual results to differ materially from the statements contained herein. The Company`s third quarter 2005 financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including the failure of Applied Imaging to develop successfully its cancer diagnostics or genetic instrument business and other such factors as set forth in "Business -- Additional Factors that Might Affect Future Results," commencing on page 11 of Applied Imaging`s Form 10-K for 2004, filed with the Securities and Exchange Commission on April 27, 2005. The forward-looking statements in this news release are made as of November 14, 2005, and Applied Imaging is under no obligation to revise or update the forward-looking statements.
Contacts:
For More Information:
CCG Investor Relations
Crocker Coulson, President
10960 Wilshire Boulevard, Suite 2050
Los Angeles, CA 90024
(310) 231-8600
crocker.coulson@ccgir.com
Applied Imaging Corp.
Terry Griffin, Chief Financial Officer
120 Baytech Drive,
San Jose, CA 95134
(408) 719-6400
tgriffin@aicorp.com
APPLIED IMAGING CORP. AND SUBSIDIARIES
Consolidated Statement of Operations
and Comprehensive Income (Loss)
(in thousands, except per share data)
(Unaudited)
Three Months ended Nine Months ended
September 30, September 30, September 30, September 30,
2005 2004 2005 2004
Revenues $4,933 $5,709 $14,735 $14,895
Cost of revenues 1,746 2,535 5,785 6,103
Gross profit 3,187 3,174 8,950 8,792
Operating expenses
Research and
development 800 887 2,555 2,622
Sales and
marketing 1,393 1,619 4,115 4,956
General and
administrative 1,065 910 3,130 3,040
Total operating
expenses 3,258 3,416 9,800 10,618
Operating loss (71) (242) (850) (1,826)
Other income/
(expense) and tax (291) 5 (459) (85)
Net loss $(362) $(237) $(1,309) $(1,911)
Net loss per share
- basic and diluted $(0.08) $(0.05) $(0.27) $(0.43)
Weighted average
shares outstanding
- basic and diluted 4,784 4,784 4,779 4,471
Selected Consolidated Balance Sheet Data
(in thousands)
(Unaudited)
September 30, December 31,
2005 2004
Cash and cash
equivalents $3,157 $3,927
Restricted cash 176 193
Working capital (691) 603
Total assets 11,929 14,032
Total stockholders`
equity 2,040 3,436
SOURCE Applied Imaging Corp.
Crocker Coulson, President of CCG Investor Relations, +1-310-231-8600,
crocker.coulson@ccgir.com, for Applied Imaging Corp.; or Terry Griffin, Chief
Financial Officer of Applied Imaging Corp., +1-408-719-6400, tgriffin@aicorp.com
http://www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
News Provided by COMTEX
Jetzt klares Kaufniveau. Spätestens wenn das 4. Q. positiv wird gehts ab.
tasmandevil
* Q3 Revenue $4.9 Million, Year-to-Date $14.7 million * Increased Investment in Circulating Tumor Cell Application Development
SAN JOSE, Calif., Nov 14, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Applied Imaging Corp. ("Applied Imaging") (Nasdaq: AICX), the leading supplier of automated digital imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications, today announced financial and operating results for the third quarter and nine month period ended September 30, 2005.
Total revenues for the quarter ended September 30, 2005 were $4.9 million. Revenues for the comparable period in 2004, at $5.7 million, were positively impacted by the release of Ariol 2.0, allowing system sale deferrals of $0.8 million from prior periods to be recognized.
Total revenues for the nine months ended September 30, 2005 were $14.7 million. This compares to revenues for the first nine months of 2004 of $14.9 million. Revenues for the first nine months of 2004 included system sale deferrals related to the release of Ariol 2.0 of $0.8 million.
The Company`s operating loss for the three months ended September 30, 2005 was $71,000 versus an operating loss of $242,000 for the equivalent period in 2004. The operating loss for the nine months ended September 30, 2005 was $850,000 compared to an operating loss for the first nine months of 2004 of $1.8 million.
The Company`s net loss for the three months ended September 30, 2005 was $362,000 versus a net loss of $237,000 for the equivalent period in 2004. The net loss for the nine months ended September 30, 2005 was $1.3 million compared to a net loss for the first nine months of 2004 of $1.9 million.
Robin Stracey, President and CEO, said, "We are pleased with our progress this quarter. Third quarter revenues were again in line with our expectation and though our net income was negatively impacted by adverse fluctuations in the dollar-pound exchange rate and the settlement of our tax dispute with the Inland Revenue in the UK, we came close to operating profitability this quarter in spite of our increased level of investment in the circulating tumor cell initiative. We had previously disclosed the tax dispute as a contingent liability of $1.1 million and were pleased to be able to finally settle the matter for $211,000."
Gross profit for the quarter was $3.2 million, representing a gross margin of 65%, up from 56% for the third quarter of 2004. Gross margin for the nine months ending September 2005 was 61%, up from 59% in the comparable prior year period.
Operating expenses for the quarter, inclusive of $515,000 for the CTC, Inc. subsidiary, were $3.3 million, a 5% decrease from the $3.4 million in the third quarter of 2004. Operating expenses for the nine-month period ended September 30, 2005, inclusive of $1.1 million for the CTC, Inc. subsidiary, were $9.8 million, an 8% decrease from the $10.6 million for the comparable 2004 period.
"2005 to date has been devoted to resolving legacy issues, solidifying the performance of our core imaging business and pushing forward with our circulating tumor cell initiative", continued Mr. Stracey. "There are three key elements to our long term growth strategy. Firstly, we intend to continue to enhance the profitability of our clinical cytogenetics business through the incremental rollout of high value new software releases, leverage of our installed base of over 4,000 units around the world and ongoing productivity improvement initiatives. Secondly, we intend to capitalize on the unique attributes of our Ariol(R) pathology workstation as a powerful tool for biopharma companies evaluating the efficacy of candidate cancer drugs. Seven leading biopharma companies have now purchased at least one Ariol(R) and we expect to further enhance the system`s value and our opportunity going forward by expanding our offering to include additional, fee-based, customization services. Thirdly, we intend to continue to invest directly, and with a strategic partner, in the development of a leading edge system for the detection, quantification and analysis of tumor cells in the circulating blood of cancer patients. We anticipate that this system, designed around the established analytical capabilities of the Ariol(R) platform, would have the potential to transform the diagnosis and monitoring of the disease and would introduce the Company to what is expected to be a significant new growth market. Additionally, we continue to focus on efficiency and process improvement."
Mr. Stracey added, "Against these goals, we accomplished a number of key milestones in the third quarter. In cytogenetics, we released CytoVision 3.7, the third in a series of important new releases this year aimed at strengthening our competitive position and further enhancing the profitability of our clinical cytogenetics business. In pathology, we released Ariol(R) 2.1 and added several important new accounts to our marquee list of biopharma and translational research customers. In CTC we made progress in our efforts to adapt the Ariol(R) rare cell detection algorithm for use with circulating tumor cells and in our efforts to optimize several of the components of the kit that we anticipate will be the captive consumable component of the system. And a good example of our progress in process improvement is the 58% reduction we have seen in inventory between December 2004 and September 2005 as a result of the adoption of more efficient supply chain management practices."
Financial Condition
As of September 30, 2005, the Company had cash and cash equivalents of $3.2 million, compared to $3.0 million at June 30, 2005 and $3.9 million at December 31, 2004.
Outlook
The Company reaffirms its full year revenue projection of approximately $20 million and expects to achieve operating profitability in its core imaging business in the fourth quarter.
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications. The Company develops, manufactures and markets a range of scanning and image analysis systems for both conventional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens. Products are sold to hospital laboratories, cancer centers, prenatal clinics and research institutions for both research and clinical purposes. The Company has installed over 4,000 of its systems in over 1000 laboratories in more than 60 countries around the world. Beyond its core business, through its wholly-owned subsidiary, CTC, Inc., the Company is also developing a system for the detection, quantification and characterization of tumor cells in the blood of cancer patients.
More information about Applied Imaging can be found at www.aicorp.com.
Code: AICXG
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements as defined in the Private Securities Litigation Reform Act of 1995, regarding, among other matters, the timing of the Company`s Cytovision and Ariol software releases, its ability to execute its long term growth initiatives, including successful development of its circulating tumor cell system and adapting its Ariol platform to new applications, as well as its future financial performance, financial condition, timing of operating profitability in its core imaging business, and the timing and amount of spending for its CTC, Inc. subsidiary. Forward-looking statements are based on management`s current, preliminary, expectations and are subject to risks and uncertainties, which may cause the Company`s actual results to differ materially from the statements contained herein. The Company`s third quarter 2005 financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including the failure of Applied Imaging to develop successfully its cancer diagnostics or genetic instrument business and other such factors as set forth in "Business -- Additional Factors that Might Affect Future Results," commencing on page 11 of Applied Imaging`s Form 10-K for 2004, filed with the Securities and Exchange Commission on April 27, 2005. The forward-looking statements in this news release are made as of November 14, 2005, and Applied Imaging is under no obligation to revise or update the forward-looking statements.
Contacts:
For More Information:
CCG Investor Relations
Crocker Coulson, President
10960 Wilshire Boulevard, Suite 2050
Los Angeles, CA 90024
(310) 231-8600
crocker.coulson@ccgir.com
Applied Imaging Corp.
Terry Griffin, Chief Financial Officer
120 Baytech Drive,
San Jose, CA 95134
(408) 719-6400
tgriffin@aicorp.com
APPLIED IMAGING CORP. AND SUBSIDIARIES
Consolidated Statement of Operations
and Comprehensive Income (Loss)
(in thousands, except per share data)
(Unaudited)
Three Months ended Nine Months ended
September 30, September 30, September 30, September 30,
2005 2004 2005 2004
Revenues $4,933 $5,709 $14,735 $14,895
Cost of revenues 1,746 2,535 5,785 6,103
Gross profit 3,187 3,174 8,950 8,792
Operating expenses
Research and
development 800 887 2,555 2,622
Sales and
marketing 1,393 1,619 4,115 4,956
General and
administrative 1,065 910 3,130 3,040
Total operating
expenses 3,258 3,416 9,800 10,618
Operating loss (71) (242) (850) (1,826)
Other income/
(expense) and tax (291) 5 (459) (85)
Net loss $(362) $(237) $(1,309) $(1,911)
Net loss per share
- basic and diluted $(0.08) $(0.05) $(0.27) $(0.43)
Weighted average
shares outstanding
- basic and diluted 4,784 4,784 4,779 4,471
Selected Consolidated Balance Sheet Data
(in thousands)
(Unaudited)
September 30, December 31,
2005 2004
Cash and cash
equivalents $3,157 $3,927
Restricted cash 176 193
Working capital (691) 603
Total assets 11,929 14,032
Total stockholders`
equity 2,040 3,436
SOURCE Applied Imaging Corp.
Crocker Coulson, President of CCG Investor Relations, +1-310-231-8600,
crocker.coulson@ccgir.com, for Applied Imaging Corp.; or Terry Griffin, Chief
Financial Officer of Applied Imaging Corp., +1-408-719-6400, tgriffin@aicorp.com
http://www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
News Provided by COMTEX
Jetzt klares Kaufniveau. Spätestens wenn das 4. Q. positiv wird gehts ab.
tasmandevil
mhhhh sieht interessant aus
thanks
thanks
up
Trading Spotlight
bitte einsteigen
[posting]19.139.801 von kravitz am 02.12.05 19:56:22[/posting]Mach einen Guten Eindruck...da bin ich dabei 
[posting]19.781.162 von Mr.Pain am 19.01.06 10:50:25[/posting]Kaufe ein T (macht einen...) 
Prior to joining Applied Imaging, Mr. Stracey was the Vice President and General Manager of a Chromatography and Mass Spectrometry business unit of Thermo Electron Corporation, where he was responsible for all aspects of a business unit providing sophisticated capital equipment and consumables to drug discovery, clinical and life sciences customers worldwide. Prior to that, Mr. Stracey was a Corporate Vice President of Dade Behring Inc. and the General Manager of its wholly-owned subsidiary, Syva Company, a leading supplier of specialized diagnostic reagents. Mr. Stracey has over 20 years of diagnostic and life sciences experience, and an extensive international operating background. Mr. Stracey has a BSc degree with honors in life sciences from the University of Nottingham in the United Kingdom. He is a graduate of the Executive Program at the Stanford University Graduate School of Business.
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications. The Company develops, manufactures and markets a range of scanning and image analysis systems for both conventional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens. Products are sold to hospital laboratories, cancer centers, prenatal clinics and research institutions for both research and clinical purposes. The Company has installed over 4,000 of its systems in over 1000 laboratories in more than 60 countries around the world. Beyond its core business, through its wholly-owned subsidiary, CTC, Inc., the Company is also developing a system for the detection, quantification and characterization of tumor cells in the blood of cancer patients.
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications. The Company develops, manufactures and markets a range of scanning and image analysis systems for both conventional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens. Products are sold to hospital laboratories, cancer centers, prenatal clinics and research institutions for both research and clinical purposes. The Company has installed over 4,000 of its systems in over 1000 laboratories in more than 60 countries around the world. Beyond its core business, through its wholly-owned subsidiary, CTC, Inc., the Company is also developing a system for the detection, quantification and characterization of tumor cells in the blood of cancer patients.
News Archives
Applied Imaging Corp. Receives Notice of Nasdaq Delisting
* Company Will Continue Building on Growth Strategy
SAN JOSE, Calif., Jan 23, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Applied Imaging Corp. (Nasdaq: AICX) announced today its receipt of a Nasdaq Listing Qualifications Panel (Panel) decision denying the Company`s appeal of a Nasdaq Staff Determination on December 9, 2005, which found that the Company failed to comply with the stockholders` equity requirement for continued listing set forth in Nasdaq Marketplace Rule 4310(c)(2)(B). As a result, Applied Imaging`s securities will be delisted from the Nasdaq Capital Market effective with the open of business on Wednesday, January 25, 2006.
The Company has fifteen days from January 23rd to request a review of the Panel`s decision by the Nasdaq Listing and Hearing Review Council (Council), and is considering this option. If an appeal is made, there can be no assurances that the Council will grant the Company`s request for continued listing. In any event, Applied Imaging`s quotation for its common stock is expected to appear in the "Pink Sheets" under the trading symbol "AICX" on January 25, 2006. Applied Imaging`s common stock may also be quoted in the future on the OTC Bulletin Board, provided that a market maker files the necessary application with the NASD and such application is cleared.
"While the delisting determination is obviously disappointing, we are continuing to implement our current operational, financial and strategic plans," said Applied Imaging Corp. President and CEO Robin Stracey. "We are also proactively exploring other strategic options aimed at ensuring we maximize shareholder value in the long term."
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications. The Company develops, manufactures and markets a range of scanning and image analysis systems for both conventional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens. Products are sold to hospital laboratories, cancer centers, prenatal clinics and research institutions for both research and clinical purposes. The Company has installed over 4,000 of its systems in over 1000 laboratories in more than 60 countries around the world. Beyond its core business, through its wholly-owned subsidiary, CTC, Inc., the Company is also developing a system for the detection, quantification and characterization of tumor cells in the blood of cancer patients.
More information about Applied Imaging can be found at www.aicorp.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:
This press release contains forward looking statements as defined in the Private Securities Litigation Reform Act of 1995, regarding, among other matters, the Company`s plan to appeal the Nasdaq Listing Qualifications Panel`s (Panel) delisting determination and the timing and/or results of the exploration of strategic options. Forward-looking statements are based on management`s current, preliminary, expectations and are subject to risks and uncertainties, which may cause the Company`s actual results to differ materially from the statements contained herein. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including the Company`s failure to appeal successfully the Panel`s determination and other such factors as set forth in "Business--Additional Factors that Might Affect Future Results," commencing on page 11 of Applied Imaging`s Form 10-K for 2004, filed with the Securities and Exchange Commission on April 27, 2005. The forward-looking statements in this news release are made as of January 23, 2006, and Applied Imaging is under no obligation to revise or update the forward-looking statements.
CODE: AICXG
Contacts:
For More Information:
CCG Investor Relations
Crocker Coulson, President
10960 Wilshire Boulevard, Suite 2050
Los Angeles, CA 90024
(310) 231-8600
crocker.coulson@ccgir.com
Applied Imaging Corp.
Terry Griffin, Chief Financial Officer
120 Baytech Drive
San Jose, CA 95134
(408) 719-6400
tgriffin@aicorp.com
SOURCE Applied Imaging Corp.
Crocker Coulson, President of CCG Investor Relations, +1-310-231-8600,
crocker.coulson@ccgir.com, for Applied Imaging Corp.; or Terry Griffin, Chief
Financial Officer of Applied Imaging Corp., +1-408-719-6400, tgriffin@aicorp.com
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
News Provided by COMTEX
Deswegen so bergab ??
Verrückt
tasmandevil
Applied Imaging Corp. Receives Notice of Nasdaq Delisting
* Company Will Continue Building on Growth Strategy
SAN JOSE, Calif., Jan 23, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Applied Imaging Corp. (Nasdaq: AICX) announced today its receipt of a Nasdaq Listing Qualifications Panel (Panel) decision denying the Company`s appeal of a Nasdaq Staff Determination on December 9, 2005, which found that the Company failed to comply with the stockholders` equity requirement for continued listing set forth in Nasdaq Marketplace Rule 4310(c)(2)(B). As a result, Applied Imaging`s securities will be delisted from the Nasdaq Capital Market effective with the open of business on Wednesday, January 25, 2006.
The Company has fifteen days from January 23rd to request a review of the Panel`s decision by the Nasdaq Listing and Hearing Review Council (Council), and is considering this option. If an appeal is made, there can be no assurances that the Council will grant the Company`s request for continued listing. In any event, Applied Imaging`s quotation for its common stock is expected to appear in the "Pink Sheets" under the trading symbol "AICX" on January 25, 2006. Applied Imaging`s common stock may also be quoted in the future on the OTC Bulletin Board, provided that a market maker files the necessary application with the NASD and such application is cleared.
"While the delisting determination is obviously disappointing, we are continuing to implement our current operational, financial and strategic plans," said Applied Imaging Corp. President and CEO Robin Stracey. "We are also proactively exploring other strategic options aimed at ensuring we maximize shareholder value in the long term."
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications. The Company develops, manufactures and markets a range of scanning and image analysis systems for both conventional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens. Products are sold to hospital laboratories, cancer centers, prenatal clinics and research institutions for both research and clinical purposes. The Company has installed over 4,000 of its systems in over 1000 laboratories in more than 60 countries around the world. Beyond its core business, through its wholly-owned subsidiary, CTC, Inc., the Company is also developing a system for the detection, quantification and characterization of tumor cells in the blood of cancer patients.
More information about Applied Imaging can be found at www.aicorp.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:
This press release contains forward looking statements as defined in the Private Securities Litigation Reform Act of 1995, regarding, among other matters, the Company`s plan to appeal the Nasdaq Listing Qualifications Panel`s (Panel) delisting determination and the timing and/or results of the exploration of strategic options. Forward-looking statements are based on management`s current, preliminary, expectations and are subject to risks and uncertainties, which may cause the Company`s actual results to differ materially from the statements contained herein. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including the Company`s failure to appeal successfully the Panel`s determination and other such factors as set forth in "Business--Additional Factors that Might Affect Future Results," commencing on page 11 of Applied Imaging`s Form 10-K for 2004, filed with the Securities and Exchange Commission on April 27, 2005. The forward-looking statements in this news release are made as of January 23, 2006, and Applied Imaging is under no obligation to revise or update the forward-looking statements.
CODE: AICXG
Contacts:
For More Information:
CCG Investor Relations
Crocker Coulson, President
10960 Wilshire Boulevard, Suite 2050
Los Angeles, CA 90024
(310) 231-8600
crocker.coulson@ccgir.com
Applied Imaging Corp.
Terry Griffin, Chief Financial Officer
120 Baytech Drive
San Jose, CA 95134
(408) 719-6400
tgriffin@aicorp.com
SOURCE Applied Imaging Corp.
Crocker Coulson, President of CCG Investor Relations, +1-310-231-8600,
crocker.coulson@ccgir.com, for Applied Imaging Corp.; or Terry Griffin, Chief
Financial Officer of Applied Imaging Corp., +1-408-719-6400, tgriffin@aicorp.com
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
News Provided by COMTEX
Deswegen so bergab ??
Verrückt
tasmandevil
[posting]19.835.208 von Mr.Pain am 23.01.06 10:47:51[/posting]Was heißt das für die Zukunft???
Jetzt geht die Post ab!!! Applied Imaging Corp. Retains Aquilo Partners to Explore Strategic Options
SAN JOSE, Calif., Jan 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Applied Imaging Corp. (OTC: AICX) announced today that the Company has retained investment bank Aquilo Partners to assist Management in exploring strategic alternatives to maximize shareholder value. The Company believes that now is an opportune time to launch such an initiative, given the resolution in 2005 of outstanding legacy corporate issues, enhancement of the financial and operating performance of its core businesses, and further development of its CTC, Inc. subsidiary.
"In 2005, we successfully resolved a number of significant legacy corporate issues, including restatement of our financial statements dating back to 2002, a patent infringement lawsuit, and a dispute with the UK tax authorities. At the same time, we improved our financial and operational performance in several key areas," stated Applied Imaging Corp. President and CEO Robin Stracey. "We rolled out several new high value software releases for clinical cytogenetics that further strengthened our market-leading competitive position. We also made progress in pathology with several enhancements to our Ariol(R) pathology workstation and FDA 510(k) approval of our Her-2/FISH application, the fifth application to be approved on the system. And, we have made significant progress in adapting the Ariol(R) rare cell detection algorithm for use with circulating tumor cells. Given these achievements, we think now is an appropriate time to explore alternatives that may better position us to implement our growth strategy."
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications. The Company develops, manufactures and markets a range of scanning and image analysis systems for both conventional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens. Products are sold to hospital laboratories, cancer centers, prenatal clinics and research institutions for both research and clinical purposes. The Company has installed over 4,000 of its systems in over 1000 laboratories in more than 60 countries around the world. Beyond its core business, through its wholly-owned subsidiary, CTC, Inc., the Company is also developing a system for the detection, quantification and characterization of tumor cells in the blood of cancer patients.
More information about Applied Imaging can be found at www.aicorp.com.
About Aquilo Partners
Aquilo Partners (www.aquilopartners.com) is an investment bank, located in San Francisco, California, that provides corporate finance, M&A, and strategic advisory services to public and private life science companies.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, regarding, among other matters, the timing of the Company`s exploration of strategic options and decisions, if any, that may result from this endeavor. Forward-looking statements are based on management`s current, preliminary, expectations and are subject to risks and uncertainties, which may cause the Company`s actual results to differ materially from the statements contained herein. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including the failure of Aquilo Partners to identify appropriate strategic options, the failure of the Company to execute or consummate any appropriate strategic options, and other such factors as set forth in "Business -- Additional Factors that Might Affect Future Results," commencing on page 11 of Applied Imaging`s Form 10-K for 2004, filed with the Securities and Exchange Commission on April 27, 2005. The forward-looking statements in this news release are made as of January 26, 2006, and Applied Imaging is under no obligation to revise or update the forward-looking statements.
Contacts:
For More Information:
CCG Investor Relations
Crocker Coulson, President
10960 Wilshire Boulevard, Suite 2050
Los Angeles, CA 90024
(310) 231-8600
crocker.coulson@ccgir.com
Applied Imaging Corp.
Terry Griffin, Chief Financial Officer
120 Baytech Drive
San Jose, CA 95134
(408) 719-6400
tgriffin@aicorp.com
CODE: AICXG
SOURCE Applied Imaging Corp.
Crocker Coulson, President of CCG Investor Relations, +1-310-231-8600,
crocker.coulson@ccgir.com, for Applied Imaging Corp.; or Terry Griffin, Chief
Financial Officer of Applied Imaging Corp., +1-408-719-6400, tgriffin@aicorp.com
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
News Provided by COMTEX
SAN JOSE, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Applied Imaging Corp. (Nachrichten) announced today that the Company is reaffirming its 2005 full-year revenue projection of approximately $20 million. The Company`s year to date revenues through the first three quarters of the year was $14.7 million. Applied Imaging also anticipates that its cash and cash equivalents for the fourth quarter of 2005 will be approximately the same as the $3.2 million the Company had as of September 30, 2005."We expect net income to be in the range of breakeven to $150,000, inclusive of the approximately $500,000 invested in our CTC, Inc. business during the fourth quarter," stated Applied Imaging Corp. President and CEO Robin Stracey. "In 2005, we enhanced our financial and operational performance in several key areas, and rolled out several new high-value software releases for clinical cytogenetics and pathology that further strengthened our market-leading competitive position."
Applied Imaging Corp. plans to release its results for the full year and fourth quarter of fiscal year 2005 in the first week of March 2006.
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications. The Company develops, manufactures and markets a range of scanning and image analysis systems for both conventional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens. Products are sold to hospital laboratories, cancer centers, prenatal clinics and research institutions for both research and clinical purposes. The Company has installed over 4,000 of its systems in over 1000 laboratories in more than 60 countries around the world. Beyond its core business, through its wholly-owned subsidiary, CTC, Inc., the Company is also developing a system for the detection, quantification and characterization of tumor cells in the blood of cancer patients.
More information about Applied Imaging can be found at http://www.aicorp.com/.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements as defined in the Private Securities Litigation Reform Act of 1995, regarding, among other matters, the Company`s final revenue and net income for the full year and fourth quarter of the 2005 fiscal year. Forward-looking statements are based on management`s current, preliminary, expectations and are subject to risks and uncertainties, which may cause the Company`s actual results to differ materially from the statements contained herein. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including the failure of the Company to develop and perfect a leading-edge system for the detection, quantification and analysis of tumor cells in the circulating blood of cancer patients, and other such factors as set forth in "Business--Additional Factors that Might Affect Future Results," commencing on page 11 of Applied Imaging`s Form 10-K for 2004, filed with the Securities and Exchange Commission on April 27, 2005. The forward-looking statements in this news release are made as of January 30, 2006, and Applied Imaging is under no obligation to revise or update the forward-looking statements.
Contacts: CCG Investor Relations Crocker Coulson, President 10960 Wilshire Boulevard, Suite 2050 Los Angeles, CA 90024 (310) 231-8600 crocker.coulson@ccgir.com Applied Imaging Corp. Terry Griffin, Chief Financial Officer 120 Baytech Drive San Jose, CA 95134 (408) 719-6400 tgriffin@aicorp.com CODE: AICXG
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 223 | ||
| 99 | ||
| 91 | ||
| 80 | ||
| 53 | ||
| 47 | ||
| 45 | ||
| 42 | ||
| 41 | ||
| 32 |
| Wertpapier | Beiträge | |
|---|---|---|
| 30 | ||
| 28 | ||
| 27 | ||
| 26 | ||
| 26 | ||
| 24 | ||
| 23 | ||
| 21 | ||
| 20 | ||
| 19 |
